FDA Approves OXYCODONE AND ACETAMINOPHEN — Aurolife Pharma, LLC

Aurolife Pharma, LLC announced the approval of an abbreviated new drug application ORAL OXYCODONE AND ACETAMINOPHEN, paving the way for its entry into the mid-level generic opioid market. This approval broadens manufacturer accessibility to the revenue-generating analgesic space and puts additional competitive pressure on branded players and prevailing generic formulations.